<DOC>
	<DOCNO>NCT01180894</DOCNO>
	<brief_summary>The purpose clinical trial determine whether intravenous iron supplementation anemic , critically ill trauma patient improve anemia reduces need red blood cell transfusion .</brief_summary>
	<brief_title>IV Iron Anemia Traumatic Critical Illness</brief_title>
	<detailed_description>Nearly trauma patient admit intensive care unit ( ICU ) anemic ( low red blood cell count ) . Anemia independent risk factor poor outcome , include infection , impair wound healing , death . Current therapy ICU anemia unsatisfactory : Red blood cell ( RBC ) transfusion associate increase risk immune suppression , infection , organ failure . Furthermore , use hemoglobin replacement product erythropoietin limited expense well unfavorable side effect profile . One principal cause anemia trauma ICU patient involve disturbance iron metabolism . Iron necessary make RBCs , lack iron deliver bone marrow result anemia . Trauma cause diversion iron bone marrow storage , participate generation RBCs . This diversion iron cause inflammatory protein release result tissue injury . Previous work principal investigator among ICU patient suggest benefit oral iron supplementation administer dosage similar use standard multivitamin . However , many patient able tolerate oral medication , study specific trauma patient . Additional research suggest intravenous iron supplementation effective treat anemic patient inflammatory condition , cancer inflammatory bowel disease . However , benefit intravenous iron supplementation never test among anemic ICU patient , include trauma patient . The current clinical trial evaluate risk/benefit profile intravenous iron supplementation among anemic trauma ICU patient . The study take place several academic trauma center long history participation translational research . Anemia remain devastate complication trauma . Current treatment option limit . Intravenous iron supplementation represent target , cost-effective solution pervasive problem , efficacy remains undefined .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<criteria>ICU admission trauma Adults ( age ≥ 18 year ) Anemia ( hemoglobin &lt; 12 g/dL ) ≤ 72 hour ICU admission Expected ICU length stay ≥ 7 day Active hemorrhage require RBC transfusion Iron overload ( serum ferritin concentration ≥ 1,000 ng/mL ) condition associate iron overload ( e.g. , hemochromatosis , aceruloplasminemia Chronic inflammatory condition ( e.g. , systemic lupus erythematosis , rheumatoid arthritis , ankylose spondilitis ) Preexisting hematologic disorder ( e.g. , thalassemia , sickle cell disease , hemophilia , von Willibrand 's disease , myeloproliferative disease ) Macrocytic anemia ( mean corpuscular volume ≥ 100 fL ) Current use immunosuppressive agent include corticosteroid ( e.g. , dexamethasone , hydrocortisone , methylprednisolone , prednisone , exclusive inhaled corticosteroid ) , calcinurin inhibitor ( e.g. , cyclosporine , tacrolimus ) , antimetabolites ( e.g. , azathioprine ) , biologics ( e.g. , OKT3 , thymoglobulin ) Use recombinant human erythropoietin formulation within prev 30 day Pregnancy lactation Prohibition RBC transfusion Stay ≥ 48 hour duration ICU transfer hospital History intolerance hypersensitivity either enteral intravenous iron Moribund state death imminent Enrollment clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Trauma</keyword>
	<keyword>Anemia</keyword>
	<keyword>Iron</keyword>
	<keyword>Erythropoeisis</keyword>
</DOC>